We are live on ! Find out more
CSTL icon

Castle Biosciences
CSTL

148 hedge funds and large institutions have $502M invested in Castle Biosciences in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 63 increasing their positions, 37 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

13,620% more call options, than puts

Call options by funds: $686K | Put options by funds: $5K

70% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 37

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

2% less capital invested

Capital invested by funds: $514M → $502M (-$12.4M)

1.03% less ownership

Funds ownership: 84.15% → 83.12% (-1%)

3% less funds holding

Funds holding: 153 → 148 (-5)

17% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 18

Holders
148
Holders Change
-5
Holders Change %
-3.27%
% of All Funds
2.36%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
15
Increased
63
Reduced
37
Closed
18
Calls
$686K
Puts
$5K
Net Calls
+$681K
Net Calls Change
-$112K

Top Buyers

Rank Fund Capital Flow
1
Principal Financial Group
Principal Financial Group
Iowa
+$9.19M
2
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$4.12M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$3.91M
4
GIM
Granahan Investment Management
Massachusetts
+$3.8M
5
SCM
Stonepine Capital Management
Oregon
+$2.8M

Top Sellers

Rank Fund Capital Flow
1
PCM
Portolan Capital Management
Massachusetts
-$7.99M
2
RI
RTW Investments
New York
-$6.32M
3
WA
Wasatch Advisors
Utah
-$5.93M
4
Goldman Sachs
Goldman Sachs
New York
-$2.66M
5
PAMP
Polar Asset Management Partners
Ontario, Canada
-$2.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
126
Tower Research Capital (TRC)
New York
$14K +$3.91K +160 +34%
SOW
127
State of Wyoming
Wyoming
$9.02K +$269 +11 +3%
HNB
128
Huntington National Bank
Ohio
$8.7K +$318 +13 +4%
CUAMC
129
China Universal Asset Management Company
China
$8.18K +$2.25K +92 +34%
US Bancorp
130
US Bancorp
Minnesota
$5.43K +$464 +19 +9%
Baillie Gifford & Co
131
Baillie Gifford & Co
United Kingdom
$5.11K – – –
AWM
132
Avior Wealth Management
Nebraska
$4.52K +$4.86K +199 New
RCM
133
Raleigh Capital Management
North Carolina
$4.2K +$611 +25 +16%
TWA
134
TCI Wealth Advisors
Arizona
$3.73K +$4.01K +164 New
AF
135
Allworth Financial
California
$2.98K +$3K +123 +1,538%
Daiwa Securities Group
136
Daiwa Securities Group
Japan
$2K – – –
CMBA
137
C.M. Bidwell & Associates
Hawaii
$1.7K +$1.83K +75 New
LC
138
Lindbrook Capital
California
$1.54K -$293 -12 -15%
PTC
139
Private Trust Company
Ohio
$1.36K – – –
PPC
140
Park Place Capital
Alabama
$1.2K – – –
BWM
141
Baystate Wealth Management
Massachusetts
$1.14K +$1.22K +50 New
ASN
142
Advisory Services Network
Georgia
$863 – – –
MCM
143
Manchester Capital Management
Vermont
$841 – – –
GRP
144
Global Retirement Partners
California
$619 -$1.22K -50 -65%
MTIC
145
Missouri Trust & Investment Company
Missouri
$432 – – –
AAP
146
Arax Advisory Partners
Colorado
$273 – – –
IA
147
IFP Advisors
Florida
$235 – – –
CTA
148
Colonial Trust Advisors
South Carolina
$136 – – –
PAMP
149
Polar Asset Management Partners
Ontario, Canada
– -$2.52M -107,100 Closed
Tudor Investment Corp
150
Tudor Investment Corp
Connecticut
– -$1.39M -58,903 Closed
3 4 5
6
7

CSTL Hedge Fund Activity: Q1 2023 in Review

148 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q1 2023, worth a combined $502M — down 2.4% from $514M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of CSTL and 15 opened new positions — a net loss of 3 holders — while 37 trimmed existing stakes and 63 added.

The largest buyer was Principal Financial Group, adding an estimated $9.19M. The largest seller was Portolan Capital Management, cutting an estimated $7.99M.

  • 148 institutional investors held Castle Biosciences (CSTL) as of Q1 2023, down from 153 in Q4 2022.
  • Funds reported $502M of Castle Biosciences stock for Q1 2023, down 2.4% quarter-over-quarter.
  • 15 funds opened new Castle Biosciences positions in Q1 2023 and 18 closed out, a net change of -3 holders.
  • The largest Castle Biosciences buyer in Q1 2023 was Principal Financial Group, an estimated $9.19M added.
  • The largest Castle Biosciences seller in Q1 2023 was Portolan Capital Management, an estimated $7.99M sold.

Based on aggregated 13F filings for Q1 2023.